MultiCell Licensee Markets Immortalized Cell Lines at AAPS
Monday November 15, 11:00 am ET
WARWICK, R.I.--(BUSINESS WIRE)--Nov. 15, 2004--MultiCell Technologies, Inc. (OTCBB:MUCL - News), leading supplier of functional non-tumorigenic immortalized human hepatocyte lines Fa2n-4 and EA1C-35, announced that XenoTech LLC, its marketing and manufacturing licensee, presented MultiCell's cells at the American Association of Pharmaceutical Scientists meeting November 7th - 11th in Baltimore, MD. This year's annual meeting was the highest-attended AAPS event ever, with over 4,500 registrations and over 450 exhibitors.
The AAPS conference covers a broad variety of interests in addition to drug development, which is the current target market for the Fa2N-4 cells. A XenoTech spokesperson indicated that XenoTech's new exhibit featuring the immortalized hepatocytes was well received and the number of leads generated was significantly higher than expected.
Drug induced liver injury is now the leading cause of liver failure in the U.S. As concerns about drug-drug interactions and toxicity rise, labor and animal costs rise. High throughput screening using MultiCell's hepatocytes is expected to become a preferred alternative. MultiCell's immortalized human hepatocyte lines closely resemble primary human liver cells in morphology and function. Thus they may save years of time and millions of dollars during preclinical drug discovery, development and testing stages, eliminating the problem of supply and variability that restrict the use of harvested human liver cells for enzyme induction, cellular toxicity assays and other in vitro screening. Hepatocytes express drug-metabolizing enzymes that biotransform drugs or substances ingested into the body, so they help predict the effect of a compound on human livers. MultiCell's cell lines are quite sensitive to compounds that alter the expression of CYP3A4, an essential feature of in vitro model systems when studying drug-drug interactions.
For pricing and delivery information of 6 to 96 well plates or vials, contact XenoTech LLC of Lenexa, KS, telephone 913-GET-P450 or see www.xenotechllc.com.
MultiCell is at 55 Access Road, Suite 700, in Warwick, Rhode Island. For information about MultiCell and its majority-owned Xenogenics subsidiary, which owns all rights to the Sybiol(TM) synthetic bio-liver device, call 401-738-7560 or see www.multicelltech.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
MultiCell Technologies, Inc.
Jerry Newmin, 401-738-7560
--------------------------------------------------------------------------------
Source: MultiCell Technologies, Inc.
biz.yahoo.com |
